JP2013525501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525501A5 JP2013525501A5 JP2013509268A JP2013509268A JP2013525501A5 JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5 JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013509268 A JP2013509268 A JP 2013509268A JP 2013525501 A5 JP2013525501 A5 JP 2013525501A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cyclodextrin
- composition according
- pazopanib
- modified cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 20
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 12
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 12
- 229960000639 pazopanib Drugs 0.000 claims 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 11
- PVPBHKCSQBLDEW-ZQOBQRRWSA-N (1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol 4-hydroxybutane-1-sulfonic acid Chemical compound OCCCCS(O)(=O)=O.OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O PVPBHKCSQBLDEW-ZQOBQRRWSA-N 0.000 claims 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000003002 pH adjusting agent Substances 0.000 claims 6
- 229920000858 Cyclodextrin Polymers 0.000 claims 5
- 230000003204 osmotic effect Effects 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33171510P | 2010-05-05 | 2010-05-05 | |
| US61/331,715 | 2010-05-05 | ||
| PCT/US2011/035363 WO2011140343A1 (en) | 2010-05-05 | 2011-05-05 | Pharmaceutical compositions and methods of making same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013525501A JP2013525501A (ja) | 2013-06-20 |
| JP2013525501A5 true JP2013525501A5 (cg-RX-API-DMAC7.html) | 2014-06-26 |
| JP5835717B2 JP5835717B2 (ja) | 2015-12-24 |
Family
ID=44851507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013509268A Expired - Fee Related JP5835717B2 (ja) | 2010-05-05 | 2011-05-05 | 医薬組成物およびその製造方法 |
Country Status (26)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
| LT2600930T (lt) | 2010-08-05 | 2021-04-12 | Forsight Vision4, Inc. | Injekcinis aparatas, skirtas vaisto tiekimui |
| US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| ES2864203T3 (es) | 2011-09-16 | 2021-10-13 | Forsight Vision4 Inc | Aparato de intercambio de fluido |
| CA2864736A1 (en) * | 2012-02-17 | 2013-08-22 | Pharmacyclics, Inc. | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
| AU2013228148B2 (en) * | 2012-03-08 | 2016-07-14 | Samsung Electronics Co., Ltd. | Method for controlling service in radio communication system |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CN105246438B (zh) | 2013-03-28 | 2018-01-26 | 弗赛特影像4股份有限公司 | 用于输送治疗物质的眼科植入物 |
| US11136625B2 (en) | 2013-08-28 | 2021-10-05 | Crown Bioscience, Inc. (Taicang) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same |
| CA2957548A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
| WO2016104690A1 (ja) | 2014-12-25 | 2016-06-30 | 国立大学法人京都大学 | 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー |
| EP3439591B1 (en) | 2016-04-05 | 2020-09-23 | ForSight Vision4, Inc. | Implantable ocular drug delivery devices |
| WO2018192416A1 (en) * | 2017-04-17 | 2018-10-25 | National Institute Of Biological Sciences, Beijing | Treating Male Senescence |
| TWI770246B (zh) * | 2017-08-02 | 2022-07-11 | 昊運股份有限公司 | 新穎化合物及包含其之醫藥組成物 |
| EP4249069B1 (en) * | 2018-06-07 | 2025-11-19 | Pfizer Inc. | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
| US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| SI1968594T1 (sl) * | 2005-11-29 | 2011-01-31 | Glaxosmithkline Llc | Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| WO2007121483A2 (en) * | 2006-04-18 | 2007-10-25 | Ekr Therapeutics, Inc. | Pre-mixed, ready-to-use iv bolus compositions and methods of use |
| ES2630406T3 (es) * | 2007-10-19 | 2017-08-21 | Sarcode Bioscience Inc. | Composición y procedimientos para el tratamiento de la retinopatía diabética |
| ES2494365T3 (es) * | 2008-01-30 | 2014-09-15 | Genentech, Inc. | Compuestos de pirazolopirimidina que inhiben PI3K y métodos de uso |
| JP2012533562A (ja) * | 2009-07-16 | 2012-12-27 | グラクソ ウェルカム マニュファクチュアリング ピーティーイー リミテッド | 治療法 |
| WO2011039648A1 (en) * | 2009-09-30 | 2011-04-07 | Glaxo Wellcome Manufacturing Pte Ltd. | Methods of administration and treatment |
| UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
| UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
| US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
-
2011
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/en active Active
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 CA CA2798386A patent/CA2798386A1/en not_active Abandoned
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/en not_active Ceased
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 PH PH1/2012/502159A patent/PH12012502159A1/en unknown
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Withdrawn
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525501A5 (cg-RX-API-DMAC7.html) | ||
| JP5885670B2 (ja) | 黄斑変性の処置のための組成物および方法 | |
| HRP20170021T1 (hr) | Formulacije koje sadrže 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol | |
| PE20130217A1 (es) | Composiciones farmaceuticas y metodos para su elaboracion | |
| AR070824A1 (es) | Suspensiones para inyeccion intravitrea de triamcinolona acetonido de baja viscosidad, altamente floculadas | |
| JP2011513492A5 (cg-RX-API-DMAC7.html) | ||
| JP2017527623A5 (cg-RX-API-DMAC7.html) | ||
| CA2760140C (en) | Topical solution formulations containing a corticosteroid and a cyclodextrin | |
| JP2015527402A5 (cg-RX-API-DMAC7.html) | ||
| EA201370175A1 (ru) | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство | |
| AU2003230681A1 (en) | Use of sulfoalkyl ether cyclodextrin as a preservative | |
| JP2019507756A5 (cg-RX-API-DMAC7.html) | ||
| JP2018021007A5 (cg-RX-API-DMAC7.html) | ||
| JP2013513612A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191369T1 (hr) | Farmaceutski pripravak koji sadrži antivirusni derivat dihidrokvinazolina | |
| RU2018117935A (ru) | Водная композиция, содержащая дантролен | |
| KR950016717A (ko) | 제약 조성물 | |
| JP2016505044A5 (cg-RX-API-DMAC7.html) | ||
| HRP20140016T1 (hr) | Suspenzije nanoäśestica koje sadrže karboksivinilni polimer | |
| ES2548706T3 (es) | Nanosuspensión farmacéutica | |
| WO2010053487A1 (en) | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | |
| KR102762379B1 (ko) | 안과용 조성물 | |
| JP2023502914A (ja) | ウルソデオキシコール酸の注射用組成物 | |
| JP5205909B2 (ja) | 粘膜適用液剤 | |
| JP2018526420A5 (cg-RX-API-DMAC7.html) |